Arbutus to Participate in October Investor Conferences

Rhea-AI Summary

Arbutus Biopharma Corporation (Nasdaq: ABUS) focuses on innovative therapies to combat chronic hepatitis B virus (HBV) infections and coronaviruses, including COVID-19. On September 28, 2021, the company announced participation in two key virtual investor conferences in October. The first is Chardan's 5th Annual Genetic Medicines Conference on October 4-5, featuring a fireside chat on October 5 at 4:30 PM ET. The second is the H.C. Wainwright HBV Virtual Conference on October 13, with a fireside chat at 1:00 PM ET. Webcast links are available on Arbutus' website, along with archived replays.

WARMINSTER, Penn., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that the Company will participate in the following October investor conferences:

Chardan’s 5^th Annual Genetic Medicines Conference – Virtual (October 4-5, 2021)

• Fireside Chat: Tuesday, October 5, 2021 at 4:30 pm ET
• Presenters: William Collier, President and Chief Executive Officer; Dr. Michael Sofia, Chief Scientific Officer; Dr. Gaston Picchio, Chief Development Officer; and David Hastings, Chief Financial Officer

H.C. Wainwright Hepatitis B Virus (HBV) Virtual Conference (October 13, 2021)

• Fireside Chat: Wednesday, October 13, 2021 at 1:00 pm ET
• Presenters: William Collier, Dr. Michael Sofia, Dr. Gaston Picchio, and David Hastings

The live webcast links for the fireside chats can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com. An archived replay of the webcast will be available on the Company’s website after the conference.

About Arbutus

Arbutus Biopharma Corporation is a publicly traded (Nasdaq: ABUS) biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple product candidates with distinct mechanisms of action that it believes have the potential to provide a new curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19). For more information, visit www.arbutusbio.com.

Contact Information

Investors and Media

William H. Collier
President and CEO
Phone: 267-469-0914
Email: ir@arbutusbio.com

Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com

FAQ

What conferences will Arbutus Biopharma participate in October 2021?

Arbutus Biopharma will participate in Chardan's 5th Annual Genetic Medicines Conference on October 4-5 and the H.C. Wainwright HBV Virtual Conference on October 13, 2021.

Who will present during the Chardan Conference fireside chat?

The presenters during the Chardan Conference fireside chat on October 5 include William Collier, Dr. Michael Sofia, Dr. Gaston Picchio, and David Hastings.

What is the date and time for the H.C. Wainwright conference fireside chat?

The fireside chat for the H.C. Wainwright conference will take place on October 13, 2021, at 1:00 PM ET.

Where can I access the live webcasts for Arbutus Biopharma's conferences?

Live webcasts for Arbutus Biopharma's conferences can be accessed through the Investors section of their website.

What is Arbutus Biopharma's primary focus?

Arbutus Biopharma primarily focuses on developing a cure for chronic hepatitis B virus (HBV) infections and therapies for coronaviruses.